	US 12,403,189 B2
	Immunogenic antigens
Jeffrey D. Fischer, Washington, DC (US); Clara J. Sei, Germantown, MD (US); Luke T. Daum, San Antonio, TX (US); and Gerald W. Fischer, Bethesda, MD (US)
Assigned to Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed by Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed on Oct. 20, 2021, as Appl. No. 17/506,237.
Claims priority of provisional application 63/246,360, filed on Sep. 21, 2021.
Claims priority of provisional application 63/094,472, filed on Oct. 21, 2020.
Claims priority of provisional application 63/094,116, filed on Oct. 20, 2020.
Prior Publication US 2022/0118079 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/04 (2006.01); A61K 39/09 (2006.01); A61K 39/095 (2006.01); A61K 39/102 (2006.01); A61K 39/116 (2006.01); A61K 39/385 (2006.01); A61K 47/64 (2017.01); A61P 31/16 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01)

CPC A61K 39/116 (2013.01) [A61K 39/04 (2013.01); A61K 39/092 (2013.01); A61K 39/095 (2013.01); A61K 39/102 (2013.01); A61K 39/385 (2013.01); A61K 47/6415 (2017.08); A61K 47/646 (2017.08); A61P 31/16 (2018.01); A61P 37/04 (2018.01); A61K 39/145 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/53 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6043 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/70 (2013.01)]

41 Claims

1. An immunogenic antigen comprised of:

a contiguous peptide containing one or more bacterial cell wall epitopes and one or more mimotopes of bacterial cell wall epitopes, wherein the one or more bacterial cell wall epitopes are from peptidoglycan and the one or more mimotopes mimic the one or more bacterial cell wall epitopes of peptidoglycan, wherein the contiguous peptide contains the sequence of one or more of SEQ ID NOs 9-17 and 20-23; and

a T cell stimulating epitope and/or an adjuvant.